Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Di(Hydroxyethyl)Ether SCHEMBL7502957 | 0.97 | TSHR (0.53) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| Tetraethylene Glycol SCHEMBL22614779 | 0.97 | MEN1 (0.58) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| Di(Hydroxyethyl)Ether SCHEMBL811321 | 0.86 | TSHR (0.59) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL9633934 | 0.85 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL4308047 | 0.85 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| 2-Methoxyethanol SCHEMBL6852450 | 0.83 | ALDH1A1 (0.33) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL10929546 | 0.83 | MEN1 (0.61) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| Di(Hydroxyethyl)Ether SCHEMBL15463763 | 0.82 | TSHR (0.71) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| Ethylene Glycol SCHEMBL28177382 | 0.82 | TSHR (0.36) | TSHR | |
| Di(Hydroxyethyl)Ether SCHEMBL8504021 | 0.81 | TSHR (0.53) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852607-B1 | SYNTHESIS OF STEROID SAPONINS | ONCOLOGY RES INTERNATIONAL LIMITED (AU) | 2018-10-24 | — | — | EP | disclosed |
| CN-104395333-B | Improved synthesis | 肿瘤学研究国际有限公司 | 2018-01-02 | — | — | CN | disclosed |
| US-20150105543-A1 | SYNTHESIS | ONCOLOGY RESEARCH INTERNATIONAL LIMITED (AU) | 2015-04-16 | — | — | US | disclosed |
| EP-2852607-A1 | IMPROVED SYNTHESIS | Oncology Research International Limited (AU) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013173862-A1 | IMPROVED SYNTHESIS | ONCOLOGY RESEARCH INTERNATIONAL LIMITED (AU) | 2013-11-28 | — | — | WO | disclosed |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | SHIONOGI & CO., LTD. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2455370-A1 | PHARMACEUTICAL PRODUCT CONTAINING LACTAM OR BENZENE SULFONAMIDE COMPOUND | Shionogi&Co., Ltd. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-7220783-B2 | Para-terphenyl compounds | SHIONOGI & CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7101915-B1 | P-terphenyl compounds | SHIONOGI & CO., LTD. (JP) | 2006-09-05 | — | — | US | disclosed |
| US-7074836-B1 | SUPPRESSION CELL DIFFERENTIATION OF CELL INTO ANTIBODY; SUPPRESS IMMONOGLOBULINS; ANTIALLERGENS | SHIONOGI & CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040127495-A1 | Novel para-terphenyl compounds | SHIONOGI & CO., LTD. | 2004-07-01 | — | — | US | disclosed |
| EP-0933346-B1 | NOVEL p-TERPHENYL COMPOUNDS | SHIONOGI & CO (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-0933346-A1 | NOVEL p-TERPHENYL COMPOUNDS | SHIONOGI & CO., LTD. (JP) | 1999-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127495-A1 | Novel para-terphenyl compounds | FCGR3B, FCGR2A, FCGRT | TSHR 548/4885MAPK1 3418/4885MEN1 4278/4885 |
| US-20120135997-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A LACTAM OR BENZENESULFONAMIDE COMPOUND | BACE1, STS, APP | TSHR 2737/4885MAPK1 4751/4885MEN1 4518/4885 |
| US-20150105543-A1 | SYNTHESIS | CYP17A1, CYP21A2, CYP11A1 | TSHR 2834/4885MAPK1 3483/4885MEN1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.